A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute.
As the founding chair of Department of Genomic Medicine at MD Anderson, and later as Chief Innovation Officer of the University of Texas System, Dr. Chin had developed technology-enabled platforms to facilitate the translation of genomic science and analytic insights into the practice of medicine.
Throughout her career, Dr. Chin has also been a champion for cross-industry collaboration. As the scientific director at the Belfer Applied Cancer Institute of Dana-Farber Cancer Institute and later at the Institute for Applied Cancer Science of MD Anderson Cancer Center, Dr. Chin has developed novel organizational construct to bridge across academia and industry to accelerate science-based drug discovery. Forseeing the paradigm shift in research and care driven by data and technologies, Dr. Chin founded Apricity Health, a next-generation precision medicine company to harness patient data and clinical expertise to develop better drugs and deliver better care for cancer patients.
- Cross-Sector Collaborations to Engage, Empower, and Enhance Care for the Underserved Populations
- COVID-19: How the Pandemic Reinforces the Value of Patient-centric Approach
Dr. Chin discusses how the pandemic is reinforcing the value of patient-centric approach… and by shifting the point-of-care and bringing clinical trials to patients’ homes, we are also narrowing the access disparity, especially for specialty care (like cancer) and novel therapies (like clinical trials).
- Can Medical Industry and Medical Research Live Happily Ever After?
- Big Data and AI: Transforming Research and Care
- Building a Patient-Centric, Interoperable, Digitally Connected Healthcare Ecosystem